User menu

Prospective non-interventional multicenter observational trial of first-line anti-cancer treatment in patients with metastatic renal cell cancer in Belgium

Bibliographic reference Cornelis, Natasha ; Vermassen, Tijl ; Schallier, Denis ; Machiels, Jean-Pascal ; Gil, Thierry ; et. al. Prospective non-interventional multicenter observational trial of first-line anti-cancer treatment in patients with metastatic renal cell cancer in Belgium. In: Acta Clinica Belgica, , p. 2295333714Y.000 (2014)
Permanent URL http://hdl.handle.net/2078.1/147201
  1. Belgian Cancer registry.
  2. Rosenberg Steven A., Lotze Michael T., Muul Linda M., Chang Alfred E., Avis Fred P., Leitman Susan, Linehan W. Marston, Robertson Cary N., Lee Roberta E., Rubin Joshua T., Seipp Claudia A., Simpson Colleen G., White Donald E., A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone, 10.1056/nejm198704093161501
  3. Negrier Sylvie, Escudier Bernard, Lasset Christine, Douillard Jean-Yves, Savary Jacqueline, Chevreau Christine, Ravaud Alain, Mercatello Alain, Peny Jean, Mousseau Mireille, Philip Thierry, Tursz Thomas, Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma, 10.1056/nejm199804303381805
  4. Sternberg Cora N., Davis Ian D., Mardiak Jozef, Szczylik Cezary, Lee Eunsik, Wagstaff John, Barrios Carlos H., Salman Pamela, Gladkov Oleg A., Kavina Alexander, Zarbá Juan J., Chen Mei, McCann Lauren, Pandite Lini, Roychowdhury Debasish F., Hawkins Robert E., Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial, 10.1200/jco.2009.23.9764
  5. Motzer Robert J., Hutson Thomas E., Tomczak Piotr, Michaelson M. Dror, Bukowski Ronald M., Rixe Olivier, Oudard Stéphane, Negrier Sylvie, Szczylik Cezary, Kim Sindy T., Chen Isan, Bycott Paul W., Baum Charles M., Figlin Robert A., Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma, 10.1056/nejmoa065044
  6. Motzer R. J., Interferon-Alfa as a Comparative Treatment for Clinical Trials of New Therapies Against Advanced Renal Cell Carcinoma, 10.1200/jco.20.1.289
  7. Storey D. J., McLaren D. B., Atkinson M. A., Butcher I., Liggatt S., O'Dea R., Smyth J. F., Sharpe M., Clinically relevant fatigue in recurrence-free prostate cancer survivors, 10.1093/annonc/mdr034
  8. Motzer Robert J., Bacik Jennifer, Schwartz Lawrence H., Reuter Victor, Russo Paul, Marion Stephanie, Mazumdar Madhu, Prognostic Factors for Survival in Previously Treated Patients With Metastatic Renal Cell Carcinoma, 10.1200/jco.2004.06.132
  9. Hudes Gary, Carducci Michael, Tomczak Piotr, Dutcher Janice, Figlin Robert, Kapoor Anil, Staroslawska Elzbieta, Sosman Jeffrey, McDermott David, Bodrogi István, Kovacevic Zoran, Lesovoy Vladimir, Schmidt-Wolf Ingo G.H., Barbarash Olga, Gokmen Erhan, O'Toole Timothy, Lustgarten Stephanie, Moore Laurence, Motzer Robert J., Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma, 10.1056/nejmoa066838
  10. Sternberg Cora N., Hawkins Robert E., Wagstaff John, Salman Pamela, Mardiak Jozef, Barrios Carlos H., Zarba Juan J., Gladkov Oleg A., Lee Eunsik, Szczylik Cezary, McCann Lauren, Rubin Stephen D., Chen Mei, Davis Ian D., A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update, 10.1016/j.ejca.2012.12.010
  11. Oken Martin M., Creech Richard H., Tormey Douglass C., Horton John, Davis Thomas E., McFadden Eleanor T., Carbone Paul P., Toxicity and response criteria of the Eastern Cooperative Oncology Group : , 10.1097/00000421-198212000-00014
  12. NCCN Guidelines® Updates, 10.6004/jnccn.2013.0138